Character Biosciences is a pioneering precision medicine company focused on developing targeted therapies for polygenic diseases, particularly in the field of ophthalmology. Utilizing a robust patient data platform that integrates genomics with extensive clinical and imaging data, the company aims to identify genetic drivers of disease progression and enhance therapeutic development. Founded in 2018, Character has successfully raised significant capital to support its innovative research, including a $110+ million Series B funding round in 2025. The interdisciplinary team at Character is dedicated to advancing programs in Dry Age-related Macular Degeneration (AMD) and exploring additional disease areas, leveraging their expertise in clinical science, data science, and drug discovery to improve patient outcomes.